Skip to main content

Peer Review reports

From: Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting

Original Submission
13 Feb 2023 Submitted Original manuscript
10 Mar 2023 Reviewed Reviewer Report
21 Mar 2023 Reviewed Reviewer Report - Keitaro Shimozaki
27 Mar 2023 Reviewed Reviewer Report
8 Apr 2023 Author responded Author comments - Septiara Putri
Resubmission - Version 2
8 Apr 2023 Submitted Manuscript version 2
11 Apr 2023 Author responded Author comments - Septiara Putri
Resubmission - Version 3
11 Apr 2023 Submitted Manuscript version 3
15 Apr 2023 Reviewed Reviewer Report
17 Apr 2023 Reviewed Reviewer Report
22 Apr 2023 Reviewed Reviewer Report
2 May 2023 Reviewed Reviewer Report
19 Jun 2023 Author responded Author comments - Septiara Putri
Resubmission - Version 4
19 Jun 2023 Submitted Manuscript version 4
26 Jun 2023 Reviewed Reviewer Report
5 Jul 2023 Reviewed Reviewer Report
6 Jul 2023 Author responded Author comments - Septiara Putri
Resubmission - Version 5
6 Jul 2023 Submitted Manuscript version 5
12 Jul 2023 Author responded Author comments - Septiara Putri
Resubmission - Version 6
12 Jul 2023 Submitted Manuscript version 6
13 Jul 2023 Author responded Author comments - Septiara Putri
Resubmission - Version 7
13 Jul 2023 Submitted Manuscript version 7
3 Aug 2023 Reviewed Reviewer Report
Resubmission - Version 8
Submitted Manuscript version 8
Publishing
3 Aug 2023 Editorially accepted
8 Aug 2023 Article published 10.1186/s12885-023-11253-y

You can find further information about peer review here.

Back to article page